ARAndreia Cristina Dalbello Rissati

Andreia Cristina Dalbello Rissati

*This is an algorithmically generated author record based on publicly available information.

Andreia Cristina Dalbello Rissati has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Use of an oral rehydration solution to prevent and treat dehydration during chemotherapy: a case series

    by Andreia Cristina Dalbello Rissati, Fernando Medina da Cunha, Mariana de Souza Alves, Tiago Merlo

    Introduction: Oral rehydration solutions (ORS) have been widely used for fluid replacement in clinical settings. Some studies have considered oral rehydration an alternative to intravenous hydration to prevent chemotherapy-induced nephrotoxicity. Objectives: This study aimed to evaluate the feasibility, acceptability, and efficacy of a ready-to-use ORS for hydrating cancer patients before chemotherapy. Methods: Eight chemotherapy patients at risk of dehydration were selected. Patients received ready-to-use ORS for three days before chemotherapy and were evaluated before and after chemotherapy over 4 cycles of treatment. Results: One patient died before the final evaluation. At baseline, none of the patients had either suitable hydration level or normal diuresis; 7 of them showed dehydrated mucous membranes. After the hydration protocol, 5 patients had suitable hydration level; urine concentration was normal in 6 patients; mucous membranes were hydrated in all 7 patients. Previous studies have shown the effectiveness and usefulness of oral rehydration after chemotherapy. The present study showed that administration of ready-to-use ORS before chemotherapy improved hydration levels. Conclusion: Ready-to-use oral rehydration solution can be used for hydration of cancer patients, with advantages in terms of convenience, acceptability, safety, and time. Studies with more patients may lead to definitive conclusions on its use in these conditions.

  • Open Access

    Impact of Physical Frailty on Early Intolerance to CAPOX Chemotherapy in Patients With Colon, Rectal, and Gastric Cancer

    by Isabella Pellegrini Grama Pereira Lima, Nicolle Martins Carrozzi, Talita Oliveira Silva, Karina Almeida de Brunheroti, Joyce Lucchesi, Andréia Cristina Dalbello Rissati, Lucinea Valério de Almeida Castro, Maria Carolina Santos Mendes, José Barreto Campello Carvalheira, Lígia M. Antunes‐Correa

    Background: Patients with gastrointestinal cancer often present reduction in functional capacity and develop frailty, which increases the risk of chemotherapy intolerance. We investigated whether physical frailty is associated with early intolerance to CAPOX (capecitabine+oxaliplatin) in patients with colon, rectal, or gastric cancer. Methods: This single‐center observational study included patients from the Oncogeriatrics Outpatient Clinic at Clinical Hospital at UNICAMP between October 2021 and July 2024. Data included physical, clinical, and anthropometric measures. Frailty was assessed using the Fried criteria, along with planned and modified chemotherapy regimens. Early chemotherapy intolerance was defined as dose reduction, cycle delay, regimen change, or treatment discontinuation due to toxicity within the first three CAPOX cycles. Patients were classified as with or without early chemotherapy‐related intolerance. Results: Of 82 patients, 47 (57%) showed early intolerance to treatment. These patients were older, more frequently female, and smokers; no significant differences were observed in anthropometric and oncological variables, or in frailty criteria classification. The number of frailty criteria was associated with increased risk of intolerance (OR = 2.07; CI: 1.14–3.75; p = 0.01). Among individual components, self‐reported exhaustion and reduced gait speed independently predicted higher risk (OR = 6.04; CI: 1.62–22.55; p = 0.007), while higher gait speed was protective (OR = 0.05; CI: 0.005–0.61; p = 0.01). Conclusion: Categorical physical frailty status was not associated with early toxicity in our cohort. However, the accumulation of physical frailty criteria showed a significant association with early toxicity. Among these criteria, gait speed emerged as one of the most relevant predictors of early toxicity in patients with colon, rectal, or gastric cancer treated with CAPOX. Objective assessment of the physical domain should be prioritized over subjective measures to improve treatment decisions and minimize adverse effects. Further research is needed to define standardized protocols for evaluating physical frailty in cancer patients.